Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream

Janja Ocvirk

doi:10.2478/v10019-010-0036-6

.blurhash-client-img { display: none !important; }

Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream

Radiology and Oncology

Volume 44 (2010): Issue 4 (December 2010)

By: Janja Ocvirk

Open Access

|Sep 2010

Abstract

References

Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.10.1093/annonc/mdi27916012181
Search in Google Scholar
van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.10.1056/NEJMoa080501919339720
Search in Google Scholar
Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.10.2478/v10019-009-0004-1
Search in Google Scholar
Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nurs 2007; 30: S17-26.10.1097/01.NCC.0000281758.85704.9b17666987
Search in Google Scholar
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.10.1093/jnci/92.3.20510655437
Search in Google Scholar
Erbitux. Summary of product characteristics. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-en.pdf
Search in Google Scholar
Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 cream. Radiol Oncol 2008; 42: 215-24.10.2478/v10019-008-0022-4
Search in Google Scholar
The international response to Helsinki VI - The WMA's Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, as adopted by the 52nd WMA General Assembly. Edinburgh; October 2000. Available at http://www.wma.net/en/20activities/10ethics/10helsinki/index.html
Search in Google Scholar
Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 2009; 43: 1658-66.10.1345/aph.1M24119755624
Search in Google Scholar
Li TH, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol 2009; 4: 107-19.10.1007/s11523-009-0114-019452131
Search in Google Scholar
Ocvirk J, Rebersek M. Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. [Abstract]. J Clin Oncol 2009; 27(Suppl): e15087.10.1200/jco.2009.27.15_suppl.e15087
Search in Google Scholar